← Core Scientific, Inc./tx
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | — | $971k | $15.9m | $50.4m | $836.2m | $311.4m | |
| Customer funding receivable and other current assets | — | — | — | — | $43.1m | $362.2m | |
| Total Current Assets | — | $1.3m | $85.1m | $97.0m | $904.0m | $895.5m | |
| Property, plant and equipment, net | — | $597.3m | $691.1m | $585.4m | $556.3m | $1.3b | |
| Operating lease right-of-use assets | — | — | $20.4m | $7.8m | $114.5m | $108.5m | |
| Other noncurrent assets | — | $21.0m | $9.3m | $19.6m | $24.0m | $50.3m | |
| Restricted cash | — | $13.8m | $36.4m | $19.3m | $783k | $0 | |
| Digital assets | — | $234.3m | $724k | $2.3m | $23.9m | $222.0m | |
| Deferred revenue | — | $63.4m | $77.7m | $9.8m | $18.1m | $127.6m | |
| Other current liabilities | — | — | — | — | $32.5m | $15.8m | |
| Convertible and other notes payable, net of current portion | — | $652.2m | $0 | $684.1m | $1.1b | $1.1b | |
| Warrant liabilities | — | $49.3m | — | $0 | $1.1b | $936.1m | |
| Additional paid-in capital | $24k | $1.4b | $1.8b | $1.8b | $2.9b | $3.2b | |
| Total Stockholders’ Deficit | $15k | ($64.2m) | ($409.3m) | ($596.9m) | ($820.2m) | ($962.7m) | |
| Total Assets | $15k | $346.4m | $807.7m | $712.2m | $1.6b | $2.3b | |
| Total Liabilities and Stockholders’ Deficit | $15k | $346.4m | $807.7m | $712.2m | $1.6b | $2.3b | |
| Accounts payable | — | $263k | $53.6m | $154.8m | $19.3m | $126.1m | |
| Accrued expenses | $400 | $3.7m | $18.0m | $179.6m | $69.2m | $512.0m | |
| Deferred revenue, net of current portion | — | — | — | — | $0 | $428.3m | |
| Total Current Liabilities | $400 | $4.2m | $186.8m | $488.4m | $134.6m | $781.4m | |
| Other noncurrent liabilities | — | $18.5m | $2.2m | $0 | $11.0m | $104.3m | |
| Total Liabilities | $400 | $65.6m | $1.2b | $1.3b | $2.4b | $3.3b | |
| Preferred stock; $0.00001 par value; 2,000,000 shares authorized; none issued and outstanding at December 31, 2025 and December 31, 2024 | — | — | — | 0 | 0 | 0 | |
| Common stock; $0.00001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 314,231 and 292,606 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | — | 27k | 36k | 36k | 3k | 3k | |
| Accumulated deficit | ($10k) | ($64.2m) | ($2.2b) | ($2.4b) | ($3.7b) | ($4.1b) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.